Russia vs USA - the communist propaganda. Let's check in 10 years!

Music of the week

The fall of antibody-drug conjugates. The beginning!

Sanofi ($SNY) is again trimming its oncology pipeline, walking away from an armed-antibody cancer treatment licensed from ImmunoGen ($IMGN) as it reshapes its approach to the field.
ImmunoGen disclosed that Sanofi has abandoned SAR3419, an antibody-drug conjugate designed to treat diffuse large B-cell lymphoma (DLBCL) and other blood cancers. The treatment combines an antibody engineered to target CD19--a protein expressed by tumors--with the cancer-killing agent maytansinoid, resulting in a targeted therapy.
http://www.fiercebiotech.com/story/sanofi-dumps-immunogen-cancer-drug-it-scales-back-oncology/2015-04-24?utm_medium=rss&utm_source=feedly&utm_campaign=rss
 

Mandometer? WTF???

How the cancer will be treated - it is a kind of magic...

Juno develops immunotherapy treatments for cancer. Immunotherapy involves drawing blood from a patient, engineering those cells to better fight cancer and then infusing them back into the patient. The concept relies on boosting the patient's immune system to battle the disease on its own.
http://www.bizjournals.com/seattle/blog/health-care-inc/2015/04/juno-teams-with-astrazeneca-to-explore-new-therapy.html?ana=Yahoo

Are M&A Replacing R&D In Pharma?

What a question??? It is obvious!!!
http://www.forbes.com/sites/nicolefisher/2015/04/22/are-ma-replacing-rd-in-pharma/
 

A communist propaganda

Quote of the day

Music of the week

Targeted failure... What is wrong with Ipsen?

61% down!
http://www.biocentury.com/dailynews/clinical/2015-04-16/active-biotech-ipsen-discontinue-tasquinimod-in-mcrpc

What is wrong with the compound tasquinimod?

 

The surgery

Let's build a plant!

Quote of the day

'Reverse Patent Trolls'

“A small minority of drug companies are abusing the patent system to sustain invalid patents that contain no meaningful innovations but serve to maintain their anti-competitive high-price monopoly,” Bass wrote in an e-mail
http://www.bloomberg.com/news/articles/2015-04-02/hayman-s-kyle-bass-targets-shire-in-new-drug-patent-challenges